Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
193 hedge funds and large institutions have $636M invested in Revance Therapeutics, Inc. in 2023 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 74 increasing their positions, 49 reducing their positions, and 32 closing their positions.
242% more call options, than puts
Call options by funds: $18M | Put options by funds: $5.27M
51% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 49
34% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 32
4% more funds holding
Funds holding: 186 → 193 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
29% less capital invested
Capital invested by funds: $893M → $636M (-$257M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$6.72M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$5.83M |
| 3 |
BlackRock
New York
|
+$5.71M |
| 4 |
Walleye Capital
New York
|
+$5.1M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$10.6M |
| 4 |
DM
Deerfield Management
New York
|
-$9.98M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.19M |
RVNC Hedge Fund Activity: Q4 2023 in Review
193 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2023, worth a combined $636M — down 29% from $893M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new RVNC positions and 32 closed out — a net gain of 11 holders — while 74 added to existing stakes and 49 trimmed.
The largest buyer was CIBC Asset Management, adding an estimated $6.72M. The largest seller was Fidelity Investments, cutting an estimated $15.5M.
- 193 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2023, up from 186 in Q3 2023.
- Funds reported $636M of Revance Therapeutics, Inc. stock for Q4 2023, down 29% quarter-over-quarter.
- 43 funds opened new Revance Therapeutics, Inc. positions in Q4 2023 and 32 closed out, a net change of +11 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2023 was CIBC Asset Management, an estimated $6.72M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2023 was Fidelity Investments, an estimated $15.5M sold.
Based on aggregated 13F filings for Q4 2023.